Simon Wentworth

In the 2024 US presidential election, health policy will remain a key issue for pharma. Both Donald Trump and Kamala Harris have criticized high drug prices, raising uncertainty for the industry. While Trump targeted generics, biosimilars, and international price comparisons during his term, Harris has been associated with pricing transparency and the Inflation Reduction Act (IRA), which introduced Medicare negotiations. A future Trump administration may continue aggressive pricing policies, but without a cohesive strategy, while a Harris presidency is expected to expand the IRA but could be less radical than some expect. Regardless of the election outcome, the industry faces ongoing pressure to lower costs while maintaining innovation in a strong market.

This week we’re focusing on MASH. It’s a high area of unmet medical need, and while there are more than 80 therapies currently in the pipeline, only around 5% of these are in Phase III development.

This week in The Pharma Letter Podcast, we are speaking with the chief executive of British drug development company Ellipses Pharma.

The Pharma Letter Podcast — Episode 26 — CRO sector surges in ... - The Pharma Letter

Over the last few days, attendees of the ongoing annual meeting of the Alzheimer’s Association have been arriving in Amsterdam for what has turned out to be a p

As the dust settles on this year’s Alzheimer’s Association International Conference (AAIC), the industry is left with a wealth of insight from some of the leadi

Large, privately-held European drugmakers are not typically identified with dynamism and a bold, acquisitive business strategy.

As the world watches aghast, the novel coronavirus continues to spread its tentacles around the globe, with cases of COVID-19 rising to nearly 375,000 on Tuesda

For many years, politicians, patients and drugmakers alike have warned about the risk posed by growing antimicrobial resistance, spurred on by liberal use of an

Gross domestic product (GDP) in Japan is about $5 trillion, and the country’s pharmaceutical market is one of the largest in the world, with figures from the Mi

As the recent G20 Summit kicked off, in the midst of unprecedented civil unrest, advocates and lobbyists of every stripe descended on Hamburg in an effort to pu